Journal of cardiology最新文献

{"title":"Impact of running average value of non-fasting serum triglyceride for secondary prevention of coronary artery disease","authors":"Ichiro Matsumoto MD,&nbsp;Kensaku Wada MD,&nbsp;Mizuki Kurozumi MD,&nbsp;Tsunetatsu Namba MD,&nbsp;Yuichiro Takagi MD","doi":"10.1016/j.jjcc.2026.03.011","DOIUrl":"10.1016/j.jjcc.2026.03.011","url":null,"abstract":"<div><h3>Background</h3><div>Elevated non-fasting triglyceride (TG) levels may be associated with increased risk of cardiovascular disease (CVD); however, the best way to measure TG values as an independent risk factor for CVD remains unclear. The aim of this study was to investigate whether the running average value of non-fasting serum TG (Ra-TG) measured after percutaneous coronary intervention (PCI) could be associated with the occurrence of subsequent cardiovascular events.</div></div><div><h3>Methods</h3><div>The clinical records of 1761 patients who underwent successful PCI were retrospectively examined. Ra-TG values were calculated by adding consecutive non-fasting serum TG values and dividing them by the number of measurements. Based on the Ra-TG value during the observation period of 10 years after PCI, the patients were divided into 3 groups: Ra-TG ≥175, 115–175, and &lt; 115 mg/dL. The incidence of major adverse cardiac events (MACEs; coronary-related deaths, nonfatal myocardial infarction, and new coronary stenosis of non-culprit lesions) was investigated in these groups. The associations between the incidence of MACEs and various risk factors were also investigated.</div></div><div><h3>Results</h3><div>Kaplan-Meier analysis demonstrated that patients with a Ra-TG ≥175 mg/dL had a significantly higher incidence of MACEs than those in the other two groups. A multivariate analysis indicated that the Ra-TG value was significantly associated with the incidence of MACEs. Furthermore, regardless of patients' low-density lipoprotein cholesterol levels or histories of acute coronary syndrome, a Ra-TG value of more than 175 mg/dL was associated with a higher incidence of MACEs after PCI.</div></div><div><h3>Conclusions</h3><div>A high Ra-TG value is a predictor of increased recurrence of MACEs after PCI and long-term management of TG levels using Ra-TG values may be useful for preventing CVD.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"88 2","pages":"Pages 129-135"},"PeriodicalIF":3.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147529330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of age on the relationship between peak creatine kinase levels and clinical outcomes after ST-elevation myocardial infarction.","authors":"Nao Tamura, Yuichi Saito, Osamu Hashimoto, Takanori Sato, Hideki Kitahara, Yoshio Kobayashi","doi":"10.1016/j.jjcc.2026.07.016","DOIUrl":"10.1016/j.jjcc.2026.07.016","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148653904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and predictors for symptomatic stroke within 30 days after transcatheter aortic valve implantation: insights from the LAPLACE-TAVI registry","authors":"Hiroaki Yokoyama MD, PhD, FJCC,&nbsp;Ken Yamazaki MD, PhD,&nbsp;Shun Shikanai MD, PhD,&nbsp;Misato Hamadate MD, PhD,&nbsp;Michiko Tsushima MD, PhD,&nbsp;Noritomo Narita MD, PhD,&nbsp;Maiko Senoo MD, PhD,&nbsp;Hiroaki Ichikawa MD, PhD,&nbsp;Shuji Shibutani MD, PhD,&nbsp;Kenji Hanada MD, PhD,&nbsp;Yoshiaki Saito MD, PhD,&nbsp;Kenyu Murata MD, PhD,&nbsp;Yuki Imamura MD, PhD,&nbsp;Ryosuke Higuchi MD,&nbsp;Kenichi Hagiya MD,&nbsp;Itaru Takamisawa MD,&nbsp;Mamoru Nanasato MD, PhD, FJCC,&nbsp;Nobuo Iguchi MD, PhD, FJCC,&nbsp;Morimasa Takayama MD, PhD, FJCC,&nbsp;Jun Shimizu MD, PhD,&nbsp;Hirofumi Tomita MD, PhD, FJCC","doi":"10.1016/j.jjcc.2026.02.007","DOIUrl":"10.1016/j.jjcc.2026.02.007","url":null,"abstract":"<div><h3>Background</h3><div>Stroke is a devastating complication after transcatheter aortic valve implantation (TAVI), however contemporary data on its incidence and predictors remain limited.</div></div><div><h3>Methods and results</h3><div>We analyzed 4774 consecutive patients undergoing TAVI between April 2010 and June 2024 in the prospective multicenter LAPLACE-TAVI registry. Patients with valve-in-valve procedures, investigational devices, or missing data were excluded. The primary endpoint was symptomatic stroke within 30 days after TAVI. Patients were stratified into 2 groups: Stroke (<em>n</em> = 68) and non-Stroke groups (<em>n</em> = 4706). Baseline characteristics, TAVI procedural data, and clinical outcomes were compared. Multivariate logistic regression was performed to identify predictors of periprocedural stroke.</div><div>Thirty-day symptomatic stroke occurred in 1.4% of study patients. Stroke patients more frequently had previous stroke, peripheral artery disease (PAD), frailty, and higher Society of Thoracic Surgeons (STS) scores. Nearly 90% of stroke events occurred within 5 days after TAVI. Use of self-expanding (SE) valves was more common in the Stroke group (47% vs. 32%). On multivariate analysis, PAD [odds ratio (OR): 1.70, 95% confidence interval (CI): 1.10–2.63], higher STS score (OR: 1.03, 95%CI: 1.00–1.05), and SE valve use (OR: 1.71, 95%CI: 1.16–2.53) were independent predictors.</div></div><div><h3>Conclusions</h3><div>In this large multicenter registry, the 30-day incidence of symptomatic stroke after TAVI was 1.4%. PAD, higher STS score, and SE valve use were independent predictors. Careful patient selection and procedural planning are warranted.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"88 2","pages":"Pages 102-108"},"PeriodicalIF":3.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147306282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Watchman FLX versus Amplatzer amulet for percutaneous left atrial appendage occlusion: A systematic review and meta-analysis","authors":"Vinicius Bittar de Pontes,&nbsp;Pedro E.P. Carvalho MD,&nbsp;Nicole Felix MD,&nbsp;Alleh Nogueira MD,&nbsp;Mariana R.C. Clemente MD,&nbsp;Victoria Gastaldelo,&nbsp;Alberto Preda MD,&nbsp;Philippe Garot MD","doi":"10.1016/j.jjcc.2025.12.004","DOIUrl":"10.1016/j.jjcc.2025.12.004","url":null,"abstract":"<div><h3>Background</h3><div>The comparative safety and efficacy of Watchman FLX (Boston Scientific, Marlborough, MA, USA) and Amplatzer Amulet (Abbott, Abbott Park, IL, USA) devices for left atrial appendage occlusion (LAAO) remain unclear.</div></div><div><h3>Objective</h3><div>To compare Watchman FLX and Amplatzer Amulet devices for LAAO.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed, Embase, and Cochrane Library for studies comparing Watchman FLX versus Amulet in patients with atrial fibrillation (AF) undergoing percutaneous LAAO. We applied a random-effects model to pool risk ratios (RR) with corresponding 95 % confidence intervals (CI) for binary endpoints.</div></div><div><h3>Results</h3><div>We included five studies comprising 1316 patients with AF undergoing LAAO for high bleeding risk. A total of 629 (47.8 %) patients underwent LAAO with Watchman FLX. Amulet was associated with lower rates of stroke or transient ischemic attack (TIA) (RR 2.31; 95 % CI 1.02–5.25; <em>p</em> = 0.04; I² = 0 %), but no differences were observed in terms of peridevice leak (RR 1.57; 95 % CI 0.86–2.89; <em>p</em> = 0.14; I² = 0 %) between Watchman and Amulet devices. Additionally, no differences were found in terms of device-related thrombus (RR 2.01; 95 % CI 0.87–4.68; <em>p</em> = 0.10; I² = 0 %), or pericardial effusion (RR 1.00; 95 % CI 0.17–5.96; <em>p</em> = 1.00; I² = 59.7 %) between both groups.</div></div><div><h3>Conclusion</h3><div>This meta-analysis indicates a lower risk of stroke or TIA with Amulet compared to Watchman FLX.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"88 2","pages":"Pages 109-115"},"PeriodicalIF":3.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145762816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discontinuation of statins by patient and physician sex: An observational study","authors":"Atsuyuki Watanabe MD,&nbsp;Yoshihisa Miyamoto MD, PhD,&nbsp;Hiroki A. Ueyama MD,&nbsp;Hiroshi Gotanda MD, PhD,&nbsp;Leandro Slipczuk MD, PhD,&nbsp;Kosuke Inoue MD, PhD,&nbsp;Eric Secemsky MD,&nbsp;Roger Laham MD,&nbsp;Deepak L. Bhatt MD, MPH, MBA,&nbsp;Yusuke Tsugawa MD, MPH, PhD,&nbsp;Toshiki Kuno MD, PhD","doi":"10.1016/j.jjcc.2026.02.006","DOIUrl":"10.1016/j.jjcc.2026.02.006","url":null,"abstract":"<div><h3>Background</h3><div>This observational study using the national US Medicare claim databases aimed to examine the association of patient and physician sex with statin discontinuation.</div></div><div><h3>Methods</h3><div>We used data on a 20% random sample of Medicare fee-for-service beneficiaries aged 66–99 years who initiated statins for primary prevention (absence of the historical diagnosis of myocardial infarction, ischemic heart disease, stroke, transient ischemic attack, and peripheral vascular disease) from January 2017 to June 2019. The primary outcome was early discontinuation (defined as the lack of second dispense at year 1), adjusting for patient demographics, comorbidities, concomitant medications, and physicians' age and specialty.</div></div><div><h3>Results</h3><div>Of 423,404 patients who initiated statins, 43,053 (10.2%) experienced early discontinuations. The adjusted risk of early discontinuation was similar but slightly lower when initiated by female physicians at 9.9% [95% confidence interval (CI), 9.1 to 10.6] versus male physicians at 10.3% (95% CI, 9.6 to 11.0) with an adjusted risk difference (aRD) of −0.4 percentage-points (pp) (95% CI, −0.7 to −0.2; <em>p</em> &lt; 0.001). When stratified by patient sex, the findings were similar in both female patients (aRD, −0.5 pp.; 95% CI, −0.7 to −0.2; <em>p</em> &lt; 0.001) and male patients (−0.5 pp.; 95% CI, −0.8 to −0.1; <em>p</em> = 0.007). The findings were consistent regardless of the diabetes status or the intensity of statins.</div></div><div><h3>Conclusion</h3><div>Using the nationwide administrative databases, we found that both older female and male patients were slightly less likely to experience early discontinuation of statins when prescribed by female versus male physicians, though the differences were clinically small.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"88 2","pages":"Pages 116-122"},"PeriodicalIF":3.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147306378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generation of ANP- and BNP-deficient human iPSC-derived cardiomyocytes reveals natriuretic peptide-dependent angiogenic paracrine effects.","authors":"Xiao Yang, Naoko Shiba, Shin Kadota, Jian Zhao, Michele Brunetti, Mai Iwaya, Takeshi Uehara, Yuji Shiba","doi":"10.1016/j.jjcc.2026.07.012","DOIUrl":"10.1016/j.jjcc.2026.07.012","url":null,"abstract":"<p><strong>Background: </strong>Cell therapy using pluripotent stem cell-derived cardiomyocytes (PSC-CMs) has emerged as a promising strategy for cardiac regeneration. Although transplanted PSC-CMs can contribute to remuscularization, accumulating evidence suggests that paracrine mechanisms also play an important role in functional recovery. Among potential paracrine factors, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are highly expressed in PSC-CMs; however, whether PSC-CM-derived ANP and BNP contribute to cardiac repair after transplantation remains to be determined.</p><p><strong>Methods: </strong>In this study, we generated human induced pluripotent stem cell (hiPSC) lines deficient in ANP (NPPA knockout), BNP (NPPB knockout), or both peptides using CRISPR-Cas9 genome editing. These iPSCs were differentiated into cardiomyocytes, and their characteristics and paracrine effects were then examined in vitro using endothelial cell assays and co-culture with cardiac fibroblasts.</p><p><strong>Results: </strong>ANP- and/or BNP-deficient hiPSC-derived cardiomyocytes (hiPSC-CMs) showed comparable cardiac differentiation efficiency, cell size, proliferative capacity, and susceptibility to apoptosis compared with wild-type hiPSC-CMs. In trans-well migration and Matrigel tube formation assays, conditioned medium from wild-type hiPSC-CMs significantly enhanced endothelial cell migration and tube formation compared with medium from double-knockout hiPSC-CMs lacking both ANP and BNP, suggesting that natriuretic peptides contribute to the pro-angiogenic effects of hiPSC-CMs in vitro. In contrast, co-culture with hiPSC-CMs attenuated TGF-β1-induced myofibroblast gene expression in cardiac fibroblasts regardless of natriuretic peptide deficiency, possibly reflecting minimal expression of the natriuretic peptide receptor NPRA in fibroblasts under in vitro conditions.</p><p><strong>Conclusions: </strong>These findings suggest that ANP and BNP are involved in the pro-angiogenic paracrine activity of hiPSC-CMs in vitro. This study provides genetically modified hiPSC-CM models that may serve as a platform for future in vivo transplantation studies to determine whether PSC-CM-derived natriuretic peptides contribute to cardiac repair after transplantation.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148648614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding intraplaque hemorrhage: From pathogenesis to clinical impact in atherosclerosis.","authors":"Atsushi Sakamoto, Sho Torii, Hiroyoshi Mori, Fumiyuki Otsuka, Rika Kawakami, Kenichiro Suwa, Hiroyuki Jinnouchi, Yu Sato, Norihito Nakamura, Masataka Nakano, Kenichi Sakakura, Gaku Nakazawa, Yuichiro Maekawa, Renu Virmani, Aloke V Finn","doi":"10.1016/j.jjcc.2026.07.019","DOIUrl":"10.1016/j.jjcc.2026.07.019","url":null,"abstract":"<p><p>Atherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Accumulating pathological evidence indicates that rapid plaque progression is driven not only by recurrent subclinical plaque rupture with healing but also by intraplaque hemorrhage (IPH), which can occur independently of overt luminal thrombosis. IPH is no longer regarded as a passive process that merely enlarges plaque volume through deposition of erythrocyte-derived lipids, hemoglobin, and iron. Instead, contemporary pathological studies have revealed that IPH initiates a cascade of molecular and cellular responses that actively promote plaque destabilization. Within hemorrhagic plaques, erythrocyte lysis generates oxidative stress and cholesterol crystallization, accelerating necrotic core expansion and inflammatory signaling. In parallel, hemoglobin-haptoglobin complex uptake by CD163⁺ macrophages induces a distinct macrophage phenotype characterized by vascular endothelial growth factor and pro-inflammatory cytokines secretion, increased microvascular permeability, and propagation of intraplaque angiogenesis. These macrophage-driven processes amplify endothelial dysfunction, promote proapoptotic endothelial-to-mesenchymal transition, impair fibrous-cap integrity, and paradoxically suppress stabilizing calcification, thereby creating a microenvironment highly susceptible to rupture. Importantly, these IPH-driven cellular responses do not act in isolation but converge to amplify plaque vulnerability through interconnected inflammatory, angiogenic, and structural pathways. Advances in vascular imaging have enabled in vivo detection of IPH-related plaque features, providing a translational bridge between pathological observations and clinical phenotyping. Across carotid and coronary arterial beds, imaging-detected IPH consistently correlates with accelerated lesion progression and adverse cardiovascular outcomes. Together, current evidence positions IPH as a central biological driver of plaque progression and destabilization rather than a secondary epiphenomenon. A deeper understanding of IPH-related cellular mechanisms may identify novel therapeutic targets beyond lipid lowering and improve identification of patients with intrinsically unstable atherosclerotic disease.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148630561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social determinants of cardiovascular health: From prevention to care and emerging challenges.","authors":"Haruyo Yasui, Atsushi Mizuno, Yayoi Tetsuou Tsukada","doi":"10.1016/j.jjcc.2026.07.013","DOIUrl":"10.1016/j.jjcc.2026.07.013","url":null,"abstract":"<p><p>Cardiovascular disease (CVD) is the leading cause of mortality globally and imposes a substantial disease burden. Addressing the social determinants of health (SDOH) presents a critical opportunity to reduce CVD-related mortality and disability. In Japan, CVD constitutes a major cause of death and necessitates long-term care, with current guidelines now incorporating SDOH related to CVD, indicative of a growing interest in these determinants. This review outlines the definition and conceptual frameworks of SDOH, along with its key domains: (1) Economic stability, (2) Education access and quality, (3) Social and community context, (4) Health care access and quality, and (5) Neighborhood and built environment. In addition to these established determinants, we discuss emerging SDOH such as climate change and digital health technologies, which may reshape cardiovascular risk and potentially widen existing disparities. We also summarize existing epidemiological findings and implications for intervention strategies, and outline future perspectives, including the implications of genetic testing and related ethical, legal, and social issues, as well as strategies aimed at reducing health disparities. Overall, advancing equitable cardiovascular health will require continued research, greater recognition of the role of SDOH, and efforts to address these determinants, including improving understanding of SDOH among health care professionals and the public and strengthening the evidence base for CVD and SDOH.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148630581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal changes in renal function after acute heart failure according to worsening renal function and hemoconcentration status.","authors":"Yukihiro Watanabe, Yoshiaki Kubota, Takuya Nishino, Shuhei Tara, Katsuhito Kato, Daisuke Hayashi, Yoshiki Iwade, Hideki Miyachi, Yu-Ki Iwasaki, Mitsunori Maruyama, Eitaro Kodani, Nobuaki Kobayashi, Takeshi Yamamoto, Kuniya Asai","doi":"10.1016/j.jjcc.2026.07.011","DOIUrl":"10.1016/j.jjcc.2026.07.011","url":null,"abstract":"<p><strong>Background: </strong>Worsening renal function (WRF) in acute heart failure (AHF) has been associated with poor outcomes; however, when accompanied by hemoconcentration, WRF is not necessarily associated with adverse outcomes. The associations of WRF and hemoconcentration with renal outcomes and longitudinal changes in renal function remain unclear.</p><p><strong>Methods: </strong>In this multicenter retrospective study, 2556 hospitalized patients with AHF (median 80 years; 60% male) were categorized into four groups according to WRF and hemoconcentration status. WRF was defined as a ≥20% decrease in estimated glomerular filtration rate (eGFR) from admission to discharge. Hemoconcentration was defined as concurrent increases in hemoglobin and hematocrit levels from admission to discharge. The primary outcome was a composite of initiation of maintenance dialysis, decline in eGFR to <10 mL/min/1.73 m², or ≥40% reduction in eGFR within one year after discharge.</p><p><strong>Results: </strong>The WRF/hemoconcentration group had less frequent inotrope use and lower N-terminal pro-B-type natriuretic peptide levels at discharge. The cumulative incidence of the primary outcome was 18.4%, 15.9%, and 20.0% in the No WRF/No hemoconcentration, No WRF/hemoconcentration, and WRF/No hemoconcentration groups, respectively, and was lowest at 9.5% in the WRF/Hemoconcentration group. In multivariable analysis, this group was significantly associated with a lower risk of the primary outcome, compared with the No WRF/No hemoconcentration group (subdistribution hazard ratio 0.58, 95% confidence interval 0.36 to 0.93, p = 0.025). The longitudinal changes in renal function differed significantly across the groups; the WRF/Hemoconcentration group showed an attenuated decline or even improvement in eGFR (+3.6 mL/min/1.73 m²/year), whereas the No WRF/No hemoconcentration group exhibited the steepest decline (-6.2 mL/min/1.73 m²/year).</p><p><strong>Conclusions: </strong>Renal function changes after AHF hospitalization were heterogeneous, and WRF accompanied by hemoconcentration was associated with favorable renal outcomes within one year after discharge.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac resynchronization therapy in patients with dilated phase of hypertrophic cardiomyopathy in a Japanese regional cohort.","authors":"Naoki Arima, Yuri Ochi, Toru Kubo, Yuichi Baba, Tatsuya Noguchi, Takayoshi Hirota, Naohito Yamasaki, Hiroaki Kitaoka","doi":"10.1016/j.jjcc.2026.07.017","DOIUrl":"10.1016/j.jjcc.2026.07.017","url":null,"abstract":"<p><p>Aim The dilated phase of hypertrophic cardiomyopathy (D-HCM) is associated with poor clinical outcomes. Cardiac resynchronization therapy (CRT) is an established treatment for heart failure; however, its efficacy in D-HCM, particularly in Japanese patients, remains unclear. This study aimed to evaluate clinical status after CRT in patients with D-HCM. METHODS AND RESULTS: We retrospectively identified patients with D-HCM who received CRT and were followed at Kochi Medical School Hospital between October 2004 and December 2021. Among 325 patients with HCM, 35 (10.8%) progressed to D-HCM during follow-up, and nine of these patients (25.7%) underwent CRT. Median age at CRT implantation was 64 years. At baseline, five patients (56%) were in New York Heart Association (NYHA) class II and four (44%) in class III. After CRT, eight of nine patients showed improvement or remained in NYHA class II. No statistically significant changes were observed in B-type natriuretic peptide levels or left ventricular ejection fraction after CRT. The median time to first unplanned cardiovascular hospitalization after CRT was approximately one year. CONCLUSION: In this Japanese regional D-HCM cohort, symptomatic improvement or stabilization was observed after CRT, although the findings should be interpreted cautiously because of limited sample size and concomitant medication management.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148630543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}